Relationship Between the Hypertension Stage and Hemoglobin A1c in Patients With Type 2 Diabetes

Document Type : Original Article


1 Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences Kerman, IR Iran.

2 Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences Kerman, IR Iran.

3 Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, IR Iran.


Background: It is now suggested that the hypertensive state in diabetic patients may be associated with the level of hemoglobin A1c (HbA1c). In line with this hypothesis, we aimed to compare the level of HbA1c in diabetic patients with and without hypertension to determine whether or not there is a correlation between HbA1c and the hypertension stage.
Methods: This cross-sectional survey was conducted in collaboration with the Physiology Research Center at Kerman University of Medical Sciences on 563 patients with type 2 diabetes. HbA1c was measured via the high-performance liquid chromatography (HPLC) technique. Hypertension was staged as normal, prehypertension, hypertension stage 1, or hypertension stage 2.
Results: We found no difference in the mean fasting blood glucose level and the mean HbA1c level between the different subgroups of hypertension stages; hence, the degree of hypertension was not associated with diabetes control status. The value of HbA1c was correlated with neither systolic blood pressure (P = 0.800) nor diastolic blood pressure (P = 0.215). We also failed to show any significant relationship between the intensity of physical activity and the HbA1c level (P = 0.517). Our multivariable linear regression model revealed that opium addiction was the only determinant significantly correlated with HbA1c (P = 0.038).
Conclusions: We showed no difference in the level of HbA1c between diabetic patients with and without hypertension. It appears that the degree of hypertension in such patients may not be associated with diabetes control status.


1. Sowers JR. Recommendations for special
populations: diabetes mellitus and the metabolic
syndrome. American journal of hypertension.
2003 Nov 1;16(S3):41S-5S.
2. Gyberg V, Bacquer D, Backer G, Jennings C,
Kotseva K, Mellbin L, Schnell O, Tuomilehto J,
Wood D, Rydén L, Amouyel P. Patients with
coronary artery disease and diabetes need
improved management: a report from the
EUROASPIRE IV survey: a registry from the
EuroObservational Research Programme of the
European Society of Cardiology. Cardiovascular
diabetology. 2015 Dec;14(1):133.
3. Somaratne JB, Whalley GA, Poppe KK, ter Bals
MM, Wadams G, Pearl A, Bagg W, Doughty
RN. Screening for left ventricular hypertrophy
in patients with type 2 diabetes mellitus in the
community. Cardiovascular diabetology. 2011
4. Govind S, Saha S, Brodin LÅ, Ramesh SS,
Arvind SR, Quintana M. Impaired myocardial
functional reserve in hypertension and diabetes
mellitus without coronary artery disease:
searching for the possible link with congestive
heart failure in the myocardial Doppler in
diabetes (MYDID) study II. American journal of
hypertension. 2006 Aug 1;19(8):851-7.
5. Grossman E, Messerli FH, Goldbourt U. High
blood pressure and diabetes mellitus: are all
antihypertensive drugs created equal?. Archives
of internal medicine. 2000 Sep
6. Lea JP, Nicholas SB. Diabetes mellitus and
hypertension: key risk factors for kidney
disease. Journal of the National Medical
Association. 2002 Aug;94(8 Suppl):7S.
7. Beevers G, Lip GY, O'brien E. ABC of
hypertension: the pathophysiology of
hypertension. BMJ: British Medical Journal.
2001 Apr 14;322(7291):912.
8. Deedwania PC, Fonseca VA. Diabetes,
prediabetes, and cardiovascular risk: shifting the
paradigm. The American journal of medicine.
2005 Sep 1;118(9):939-47.
9. Mcfarlane SI, Banerji M, Sowers JR. Insulin
resistance and cardiovascular disease. The
Journal of Clinical Endocrinology &
Metabolism. 2001 Feb 1;86(2):713-8.
10. De Boer IH, Kestenbaum B, Rue TC, Steffes
MW, Cleary PA, Molitch ME, Lachin JM,
Weiss NS, Brunzell JD. Insulin therapy,
hyperglycemia, and hypertension in type 1
diabetes mellitus. Archives of internal medicine.
2008 Sep 22;168(17):1867-73.
11. for the Diabetes TW, Control and Complications
Trial/Epidemiology of Diabetes Interventions
and Complications Research Group. Sustained
effect of intensive treatment of type 1 diabetes
mellitus on development and progression of
diabetic nephropathy: the Epidemiology of
Diabetes Interventions and Complications
(EDIC) study. JAMA: the journal of the
American Medical Association. 2003 Oct
12. Bell DS. Treatment of diabetic hypertension.
Diabetes, Obesity and Metabolism. 2009

13. Preis SR, Pencina MJ, Hwang SJ, D'Agostino
RB, Savage PJ, Levy D, Fox CS. Trends in
cardiovascular disease risk factors in individuals
with and without diabetes mellitus in the
Framingham Heart Study. Circulation. 2009 Jul
14. American Diabetes Association. Standards of
medical care in diabetes—2011. Diabetes care.
2011 Jan;34 (Suppl 1):S11-61.
15. Cuddy ML. Treatment of hypertension:
guidelines from JNC 7 (the seventh report of the
Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High
Blood Pressure 1). The Journal of practical
nursing. 2005;55(4):17.
16. Norlund A, Apelqvist J, Bitzén PO, Nyberg P,
Scherstén B. Cost of illness of adult diabetes
mellitus underestimated if comorbidity is not
considered. Journal of internal medicine. 2001
17. Vokonas PS, Kannel WB, Cupples LA.
Epidemiology and risk of hypertension in the
elderly: the Framingham Study. Journal of
hypertension. Supplement: official journal of the
International Society of Hypertension. 1988
18. Zhou L, Li Y, Guo M, Wu Y, Zhao L. Relations
of body weight status in early adulthood and
weight changes until middle age with
hypertension in the Chinese population.
Hypertension Research. 2016 Dec;39(12):913.
19. Lavie P, Herer P, Hoffstein V. Obstructive sleep
apnoea syndrome as a risk factor for
hypertension: population study. Bmj. 2000 Feb
20. Feinkohl I, Lachmann G, Brockhaus WR,
Borchers F, Piper SK, Ottens TH, Nathoe HM,
Sauer AM, Dieleman JM, Radtke FM, van Dijk
D. Association of obesity, diabetes and
hypertension with cognitive impairment in older
age. Clinical Epidemiology. 2018;10:853.
21. Cockcroft JR. ACE inhibition in hypertension:
focus on perindopril. American journal of
cardiovascular drugs : drugs, devices, and other
interventions. 2007;7(5):303-17.
22. Adler AI, Stratton IM, Neil HA, Yudkin JS,
Matthews DR, Cull CA, Wright AD, Turner RC,
Holman RR. Association of systolic blood
pressure with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 36):
prospective observational study. Bmj. 2000 Aug
23. Ogihara T, Asano T, Ando K, Chiba Y, Sakoda
H, Anai M, Shojima N, Ono H, Onishi Y,
Fujishiro M, Katagiri H. Angiotensin II–induced
insulin resistance is associated with enhanced
insulin signaling. Hypertension. 2002 Dec
24. Bower JK, Appel LJ, Matsushita K, Young JH,
Alonso A, Brancati FL, Selvin E. Glycated
hemoglobin and risk of hypertension in the
atherosclerosis risk in communities study.
Diabetes care. 2012 Mar 16:DC_112248.
25. Britton KA, Pradhan AD, Gaziano JM, Manson
JE, Ridker PM, Buring JE, Sesso HD.
Hemoglobin A1c, body mass index, and the risk
of hypertension in women. American journal of
hypertension. 2011 Mar 1;24(3):328-34.
26. Fagot-Campagna A, Balkau B, Simon D,
Ducimetière P, Eschwège E. Is insulin an
independent risk factor for hypertension? The
Paris Prospective Study. International journal of
epidemiology. 1997 Jun 1;26(3):542-50.
27. He J, Klag MJ, Caballero B, Appel LJ,
Charleston J, Whelton PK. Plasma insulin levels
and incidence of hypertension in African
Americans and whites. Archives of internal
medicine. 1999 Mar 8;159(5):498-503.
28. Liese AD, Mayer-Davis EJ, Chambless LE,
Folsom AR, Sharrett AR, Brancati FL, Heiss G,
Atherosclerosis Risk in Communities Study
Investigators. Elevated fasting insulin predicts
incident hypertension: the ARIC study. Journal
of hypertension. 1999 Aug 1;17(8):1169-77.
29. Vaccaro O, Imperatore G, Iovino V, Iovine C,
Rivellese AA, Riccardi G. Does impaired
glucose tolerance predict hypertension?.
Diabetologia. 1996 Jan 1;39(1):70-6.
30. Savoia C, Schiffrin EL. Vascular inflammation
in hypertension and diabetes: molecular
mechanisms and therapeutic interventions.
Clinical Science. 2007 Apr 1;112(7):375-84.

31. Karam GA, Reisi M, Kaseb AA, Khaksari M,
Mohammadi A, Mahmoodi M. Effects of opium
addiction on some serum factors in addicts with
noninsulindependent diabetes mellitus.
Addiction biology. 2004 Mar;9(1):53-8.
32. Azod L, Rashidi M, Afkhami-Ardekani M,
Kiani G, Khoshkam F. Effect of opium
addiction on diabetes. The American journal of
drug and alcohol abuse. 2008 Jan 1;34(4):383-8.
33. Rezvanfar MR, Farahany H, Rafiee M, Kaboli
S. Opium consumption challenge and diabetes
mellitus control. Iranian Journal of Diabetes and
Obesity. 2011 Jul 15;3(2):72-6.
34. Byrkjeland R, Njerve IU, Anderssen S, Arnesen
H, Seljeflot I, Solheim S. Effects of exercise
training on HbA1c and VO2peak in patients
with type 2 diabetes and coronary artery disease:
a randomised clinical trial. Diabetes and
Vascular Disease Research. 2015
35. Church TS, Blair SN, Cocreham S, Johannsen
N, Johnson W, Kramer K, Mikus CR, Myers V,
Nauta M, Rodarte RQ, Sparks L. Effects of
aerobic and resistance training on hemoglobin
A1c levels in patients with type 2 diabetes: a
randomized controlled trial. Jama. 2010 Nov
36. Harmer AR, Elkins MR. Amount and frequency
of exercise affect glycaemic control more than
exercise mode or intensity. Br J Sports Med.
2015 Aug 1;49(15):1012-4.